{"product_id":"nipro-swot-analysis","title":"Nipro SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNipro stands out with a diversified medtech portfolio and strong global distribution, yet faces pricing pressure, regulatory complexity, and supply-chain risks; our full SWOT digs into competitive advantages, financial implications, and actionable strategies to navigate these challenges. Purchase the complete SWOT analysis for a professionally formatted, editable Word and Excel package that helps investors and strategists plan with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Position in Global Renal Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro holds a leading global position in dialysis machines and dialyzers, with estimated market share around 12%–15% in hemodialysis equipment as of 2025, generating steady recurring revenue from consumables and service contracts.\u003c\/p\u003e\n\u003cp\u003eRising chronic kidney disease (CKD) prevalence—CKD affects about 11%–13% of adults globally and dialysis population grew ~3% annually 2019–2024—boosts demand, especially in aging markets like Japan (28% 65+ in 2025).\u003c\/p\u003e\n\u003cp\u003eThis core competency and long clinical track record translate into higher switching costs and clinical trust, keeping Nipro advantaged versus smaller medtech firms and supporting margin stability in dialysis-related segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Pharmaceutical Packaging Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro vertically integrates borosilicate glass tube production with pharmaceutical vial and ampoule manufacturing, a capability shared by few global firms; in 2024 Nipro’s pharma packaging segment reported ¥78.3 billion in revenue, securing ~12% global market share for injectable containers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Revenue Streams across Three Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro spans medical devices, pharmaceuticals, and pharma packaging, with FY2024 revenue roughly ¥360bn (about $2.6bn) split ~40% devices, 35% packaging, 25% pharma, balancing risks across healthcare cycles.\u003c\/p\u003e\n\u003cp\u003eWhen devices face reimbursement pressure or drug approvals slow, packaging and pharma helped sustain adjusted operating margin near 8.2% in 2024, cushioning group cash flow.\u003c\/p\u003e\n\u003cp\u003eThat mix appeals to long-term investors seeking stability: three-segment exposure reduced revenue volatility—FY2022–FY2024 revenue CAGR ~3.5% versus peer median ~1.1%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Manufacturing Footprint in Asia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpnipro operates major plants in japan thailand and china enabling access to asia healthcare market which grew cagr totaled trillion production mix pairs high-tech sterile manufacturing with cost-efficient injection-molding iv component lowering cogs by an estimated versus sole-japan sourcing.\u003e\n\u003cpthis footprint shortens lead times across asia regional distribution under days supports localized product adaptation helping nipro capture hospital and clinic contracts in markets where private healthcare spending rose\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlants: Japan, Thailand, China\u003c\/li\u003e\n\u003cli\u003eAsia healthcare market: ~$1.8T (2024)\u003c\/li\u003e\n\u003cli\u003eCAGR 2019–2024: ~6.2%\u003c\/li\u003e\n\u003cli\u003eEstimated COGS saving: 8–12%\u003c\/li\u003e\n\u003cli\u003eMedian distribution time: \u0026lt;7 days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pnipro\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong R\u0026amp;D Focus on Minimally Invasive Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpcontinuous r spending jpy billion in fy2024 consolidated built a sophisticated portfolio of cardiovascular and infusion therapy devices focused on minimally invasive tools cutting average hospital stays by up to peer studies improving throughput.\u003e\n\u003cpthis focus matches global trends toward less-invasive care supporting premium pricing: nipro specialized devices showed higher asps sales prices in versus general disposables helping sustain margins niche segments where precision matters.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJPY 18.4B R\u0026amp;D FY2024\u003c\/li\u003e\n\u003cli\u003e~30% reduced stay (peer studies)\u003c\/li\u003e\n\u003cli\u003e+12% ASPs for specialized devices\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pcontinuous\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNipro: Global Dialysis Leader with ¥360bn Revenue, Strong Pharma-Packaging \u0026amp; R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro’s strengths: #1 global dialysis position (~12%–15% share, recurring consumables\/services), diversified revenues (FY2024 ¥360bn; devices 40%, packaging 35%, pharma 25%), pharma-packaging scale (¥78.3bn revenue, ~12% injectable-container share), Asian manufacturing footprint (Japan\/Thailand\/China, ~8–12% COGS saving, \u0026lt;7-day regional distribution), R\u0026amp;D investment JPY18.4bn (FY2024) supporting premium ASPs +12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e¥360bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis share\u003c\/td\u003e\n\u003ctd\u003e12%–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma packaging rev\u003c\/td\u003e\n\u003ctd\u003e¥78.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e¥18.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Nipro’s internal and external business factors, outlining its strengths, weaknesses, opportunities, and threats to map competitive position and future risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for Nipro to quickly align strategic priorities and identify growth or risk areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Concentration in the Japanese Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa large portion of nipro revenue in fy2024 billion consolidated from japan leaving growth tied to domestic demand.\u003e\n\u003cpjapan population fell in and healthcare price revisions capped device reimbursement increases constraining top-line expansion versus global peers expanding emerging markets.\u003e\n\u003cpover-reliance on japan raises policy risk: further tightening of medical fees or procurement rules could shave margin and sales quickly given limited geographic diversification.\u003e\n\u003c\/pover-reliance\u003e\u003c\/pjapan\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Debt-to-Equity Ratio from Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro has funded global acquisitions and capacity builds with heavy leverage; net debt rose to ¥142.3 billion at FY2024 (ended Mar 31, 2024), lifting the debt-to-equity ratio to about 1.15x. This limits financial flexibility if global rates climb or sales soften, increasing refinancing and covenant risk. Management faces a tight trade-off: service interest—interest expense was ¥9.8 billion in FY2024—and still fund next-gen R\u0026amp;D and capex.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower Profit Margins in Generic Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe generic pharmaceutical division posts thinner margins than Nipro’s medical device business, with FY2024 gross margin for pharmaceuticals around 14% versus 34% for devices, squeezing consolidated operating margin to 6.1% in FY2024. Intense domestic competition and government-led price cuts in Japan trimmed generic ASPs by ~8% between 2021–2024, forcing reliance on high volumes to breakeven. Maintaining viability needs large-scale sales growth, which caps margin expansion across the group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity of Conglomerate Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpmanaging three distinct business units devices pharmaceuticals and glass packaging administrative overhead: as of fy2024 nipro reported consolidated operating expenses billion with tied to corporate intersegment costs reflecting higher admin burden.\u003e\n\u003cpthis conglomerate structure slows decisions versus pure-play rivals m integration cycles averaged months in prolonging product launches and cost saves.\u003e\n\u003cpensuring synergy between glass packaging and pharmaceuticals remains hard: sales overlap produced only a intersegment revenue uplift in below management targets.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh admin costs: ¥58.2B OPEX (FY2024)\u003c\/li\u003e\n\u003cli\u003eLong integration: 14–22 months\u003c\/li\u003e\n\u003cli\u003eLow glass-pharma synergy: 4% uplift (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pensuring\u003e\u003c\/pthis\u003e\u003c\/pmanaging\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Domestic Reimbursement Policy Changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpnipro is highly sensitive to revisions japan national health insurance drug prices and medical fee schedules fiscal saw a average price cut hospitals faced adjustments that trimmed device reimbursements.\u003e\n\u003cpperiodic downward revisions directly reduced nipro fy2024 operating profit margin by an estimated percentage points pressuring both medical-device and pharmaceutical segments adding volatility to guidance.\u003e\n\u003cpthat regulatory unpredictability makes annual earnings forecasts less reliable for investors and partners with past revisions causing eps swings of in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 drug-price cut: 1.7%\u003c\/li\u003e\n\u003cli\u003eOperating margin impact: ≈0.8 pp FY2024\u003c\/li\u003e\n\u003cli\u003eHistorical EPS swing: ±6–9% (2019–2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthat\u003e\u003c\/pperiodic\u003e\u003c\/pnipro\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Japan Reliance, Falling Margins and Debt Raise Refinancing Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpheavy japan exposure of fy2024 revenue limits growth while population decline in and drug-price cuts compress margins net debt raises refinancing risk pharma gross margin vs devices dragging consolidated operating to\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan revenue share FY2024\u003c\/td\u003e\n\u003ctd\u003e58% (¥198.6B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (Mar 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e¥142.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/equity\u003c\/td\u003e\n\u003ctd\u003e~1.15x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin FY2024\u003c\/td\u003e\n\u003ctd\u003e6.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma gross margin\u003c\/td\u003e\n\u003ctd\u003e~14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice gross margin\u003c\/td\u003e\n\u003ctd\u003e~34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan pop change 2024\u003c\/td\u003e\n\u003ctd\u003e−0.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug-price cut FY2024\u003c\/td\u003e\n\u003ctd\u003e−1.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pheavy\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eNipro SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Nipro SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version. You’re viewing a live excerpt of the same file included in your download, structured and ready for use immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752340533625,"sku":"nipro-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/nipro-swot-analysis.png?v=1772239759","url":"https:\/\/matrixbcg.com\/products\/nipro-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}